Early‐stage clinical trials of STAT3 inhibitors in a variety of disease settings have been reported48 and although STAT3 inhibitors do not yet have approvals to treat cancer it is a potential therapeutic target for subgroups of DLBCL. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.